Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Key PointsIt's a cancer medication with immense potential.
Trading
Tuesday, 8 September 2026
Independent coverage of global markets, trade and finance
Trading
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Key PointsIt's a cancer medication with immense potential.